Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives Flovent aerosol approval

GlaxoSmithKline receives Flovent aerosol approval

24th March 2006

GlaxoSmithKline (GSK) has revealed that the Food and Drug Administration (FDA) of the United States has approved Flovent HFA for use in children.

The FDA approval for the inhaled corticosteroid (ICS) aerosol for use in asthmatic children aged four to 11 means that the children in this age range can now benefit from what GSK says is the “most prescribed ICS” on the market.

Flovent HFA works by helping to reduce inflammation in the airways, something that is considered one of the main elements of asthma.

Clinical trials of Flovent found that it was successful in reducing nighttime awakenings due to complications associated with asthma when taken twice daily and also improved expiratory flow and reduced the use of daily rescue albuterol.

The aerosol used to administer the Flovent HFA is environmentally-friendly, GSK says, with hydrofluoroalkane replacing the chlorofluorocarbon (CFC) propellant.

According to the US Centres for Disease Control, 3.6 million children between the ages of five and 11 have been diagnosed with asthma.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.